Tuesday, November 1, 2022
11:00AM – 12:00PM ET
Please note this TeleECHO program is 11:00AM Eastern, 10:00AM Central, 9:00AM Mountain and 8:00AM Pacific.
PROGRAM OVERVIEW
This live virtual TeleECHO program will explore key clinical practice insights for patients with advanced or metastatic basal cell or cutaneous squamous cell carcinomas (NMSCs). Over the course of this activity there will be discussion of the data from clinical trials assessing the clinical profiles of new systemic therapies with different mechanisms of action for the treatment of patients with advanced NMSCs failing or not amenable to surgery or radiation; integrating methods for identifying and managing side effects associated with new systemic therapies for the treatment of patients with advanced NMSCs into routine clinical practice; categorizing the types of patients with unresectable NMSCs who may benefit from new systemic therapies for the treatment of advanced NMSCs; and lastly enhancing patient management including care coordination through participation in interdisciplinary care teams for those with advanced NMSCs failing or not amenable to surgery or radiation.
PRESENTING FACULTY
Yana Najjar, MD
Assistant Professor of Medicine
Melanoma Program; Cancer Immunotherapeutics Center
Division of Oncology; UPMC Hillman Cancer Center
University of Pittsburgh
Pittsburgh, PA
TARGET AUDIENCE
This activity is designed to meet the educational needs of community-based dermatologists, oncologists, and dermato-oncologists who care for patients with advanced or metastatic basal cell or cutaneous squamous cell carcinomas.
EDUCATIONAL OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Evaluate data from clinical trials assessing the clinical profiles of new systemic therapies with different mechanisms of action for the treatment of patients with advanced NMSCs failing or not amenable to surgery or radiation
- Integrate methods for identifying and managing side effects associated with new systemic therapies for the treatment of patients with advanced NMSCs into routine clinical practice
- Categorize the types of patients with unresectable NMSCs who may benefit from new systemic therapies for the treatment of advanced NMSCs
- Enhance patient management including care coordination through participation in interdisciplinary care teams for those with advanced NMSCs failing or not amenable to surgery or radiation
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live virtual activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with non-melanoma skin cancer.
CNE Credits: 1.0 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at [email protected].
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
